2022-RA-906-ESGO Acid ceramidase (ASAH1) expression is associated with improved progression- and overall survival in high-grade serous ovarian cancer patients

Lars Christian Hanker; Ahemd El-Balat; Thomas Karn; Uwe Holtrich; Bendickt Decker; Jakobus Pfisterer; Heide Gevensleben; Stefan Kommoss

doi:10.1136/ijgc-2022-ESGO.589

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

PDF

Ovarian cancer

2022-RA-906-ESGO Acid ceramidase (ASAH1) expression is associated with improved progression- and overall survival in high-grade serous ovarian cancer patients

Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Hanker LC, El-Balat A, Karn T, et al

2022-RA-906-ESGO Acid ceramidase (ASAH1) expression is associated with improved progression- and overall survival in high-grade serous ovarian cancer patients

International Journal of Gynecologic Cancer 2022;32:A276.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password